logo
#

Latest news with #MorganLuttrell

Border apprehensions hit record low in dramatic turnaround from Biden era
Border apprehensions hit record low in dramatic turnaround from Biden era

Fox News

time01-08-2025

  • Politics
  • Fox News

Border apprehensions hit record low in dramatic turnaround from Biden era

The southern border has largely gone quiet. United States Border Patrol Chief Michael Banks posted to X on Friday that southwest border apprehensions hit a monthly record low in July, with only 4,399 apprehensions. For the third month in a row, there have been zero releases. This is the new all-time record low, beating the prior record low of 6,070 in June. In July, it averages out to 141 apprehensions per day at the southern border. At the height of the Biden-era crisis, there were 10,000-plus apprehensions on some days in December 2023. The high number of crossings resulted in an intense strain on resources in small border communities for years, as agents struggled to keep up with the demand while also dealing with responsibilities at the legal ports of entry. In addition, many migrants were bused at the request of some Republican leaders to Democratic-run areas like New York City. During the Biden administration, the record high was December 2023, with 249,785 apprehensions, the majority of which were released into the U.S. The nosedive in numbers is seen as a major victory by Republicans and the Trump administration. "The border is secure again — as it should be. Strong policies equal quiet borders," Rep. Morgan Luttrell, R-Texas, posted to X. At the start of President Donald Trump's second term, troops were deployed to the border, and the CBP One app that was commonly used for people crossing illegally to claim asylum was shuttered. The app was replaced with CBP Home, which is used for people to self-deport. The Department of Homeland Security has been touting for months an offer to give people $1,000 and free travel outside the U.S. if they have not committed other crimes. Deportation efforts are now underway throughout the U.S., as the administration is honing in on areas with sanctuary policies, with push back from Democratic officials at different levels of Congress. Still, border and immigration enforcement is expected to get a resources boost with the recent passage of the Trump-backed spending bill, dubbed the One Big Beautiful Bill Act. Billions were allocated for border security efforts, including to pay back states for costs incurred during the Biden administration, and ICE is now beginning recruitment for thousands more agents they've been given the budget to hire.

IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Associated Press

time21-05-2025

  • Health
  • Associated Press

IBN Coverage: Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 20, 2025 ( NEWMEDIAWIRE ) - Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans - a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he's pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell is helping lead legislative efforts to fund clinical trials through the VA and Pentagon, despite resistance from some conservatives and recent regulatory setbacks like the FDA's rejection of an MDMA therapy from Lykos Therapeutics. Amid this shift, NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics are emerging as leaders in veteran-focused psychedelic innovation. HOPE is developing ketamine-based treatments for acute suicidality and major depression and is building a nationwide network of… Read More NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store